Skip to content

H2020

TRIC-TB

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Programme
Horizon 2020
Started
Ends
Duration
58 months
Total cost
EUR 8,373,250
EU contribution
EUR 6,926,375
Participants
3 from 3 countries
Topic
H2020_IMI2-2018-16-06
Grant agreement
853800

Coordinated by Bioversys AG (CHSwitzerland).

Consortium

EU contribution per participant as the open data of CORDIS states it; for a participant with linked third parties it may include their share, and a participant whose amount the data does not hold or cannot make consistent shows Not stated. A participant who left the project is not listed; see the history below.

Members of the consortium
OrganisationCountryRoleEU contributionRecognised by
Bioversys AGCHSwitzerlandCoordinatorEUR 6,926,375PIC (1.00)
Glaxosmithkline Investigacion y Desarrollo SLESSpainParticipantEUR 0PIC (1.00)
BioVersys SASFRFranceThird partyNot statedPIC (1.00)

Changes of the consortium

First seen on with 3 participants from 3 countries.

A snapshot of each project's members is taken once a month; a change is recorded when a snapshot differs from the one before. A project with no change listed has had the same members since it was first observed.

Project page on CORDIS (opens in new tab)

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.